Jeremy Thomas

Multi-omic machine learning predictor of breast cancer therapy response

Stephen‐John Sammut, Mireia Crispin‐Ortuzar, Suet‐Feung Chin et al. · Nature · 2021 · 586 citations · Full text

Addressing overtreatment of screen detected DCIS; the LORIS trial

Adele Francis, Jeremy Thomas, Lesley Fallowfield et al. · European Journal of Cancer · 2015 · 365 citations

Medical Diagnostics, Loris Trial, Point-of-care Testing +3

Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases

Sarah J. Aitken, Jeremy Thomas, Simon P. Langdon et al. · Annals of Oncology · 2009 · 184 citations · Full text

Breast Oncology, Oncology, Her2 Expression +10

Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial

Helena Earl, Louise Hiller, Janet Dunn et al. · The Lancet Oncology · 2015 · 133 citations · Full text

Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601)

John M.S. Bartlett, Alison F. Munro, Janet Dunn et al. · The Lancet Oncology · 2010 · 127 citations · Full text